Corporate Profile

We are a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Our initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, which play key roles in regulating fibrosis. We believe our product candidates are distinct from the current generation of antifibrotic agents and have the potential to significantly improve patients’ clinical outcomes and enhance their quality of life.

Our lead product candidate is an inhaled galectin-3 modulator, GB0139, currently in a Phase 2b study for the treatment of idiopathic pulmonary fibrosis. Our pipeline also includes an orally active galectin-3 inhibitor, GB1211, that is expected to be part of (i) a phase 2 trial for the potential treatment of NSCLC in combination with an anti-PD1/-L1 product and (ii) a phase 1b/2a trial in liver cirrhosis, as well as an orally active LOXL2 inhibitor, GB2064, that is part of an ongoing phase 2 trial for the potential treatment of myelofibrosis.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

05 Jan '22
Dr. Oestreich brings extensive experience in business and drug development BOSTON , Jan. 05, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of a
20 Dec '21
Company has enrolled 10 of the targeted 16 patients in the trial Anticipates interim data in mid-2022 and topline data from full trial in 2H 2022 BOSTON , Dec. 20, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a publicly listed company focused on the development of novel treatments for
13 Dec '21
GB1211 observed to be safe and well tolerated in initial twelve randomized subjects, including six hepatically impaired liver cirrhosis patients Galecto initiates Part 2 of Phase 1b/2a trial in patients with liver cirrhosis BOSTON , Dec. 13, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc.